NCT03244384 2026-03-19
AMBASSADOR
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
6 trialsNCT05092958 2026-03-19
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02496208 2026-03-18
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06764095 2026-02-12
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
Phase 4 Recruiting
NCT07087860 2025-12-09
RECIPE-B1
Mayo Clinic
Phase 2 Recruiting
NCT05756569 2025-07-28
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Emory University
Phase 2 Recruiting